Arcus Biosciences (RCUS) EBIT Growth (3y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 32.96% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -29.67% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -50.81% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 13.47% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.35% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -12.10% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 55.96% |
| 10 | Arcus Biosciences | 3.18 Bn | 2.36 Bn | - | -15.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.93% |
| Dec 31, 2025 | -15.49% |
| Sep 30, 2025 | -26.59% |
| Jun 30, 2025 | 51.24% |
| Mar 31, 2025 | -22.11% |
| Dec 31, 2024 | -33.26% |
| Sep 30, 2024 | -10.35% |
| Jun 30, 2024 | -11.66% |
| Mar 31, 2024 | 39.64% |
| Dec 31, 2023 | -20.68% |
| Sep 30, 2023 | -276.91% |
| Jun 30, 2023 | -22.30% |
| Mar 31, 2023 | -44.67% |
| Dec 31, 2022 | -61.62% |
| Sep 30, 2022 | -44.40% |
| Jun 30, 2022 | -33.26% |
| Mar 31, 2022 | -52.82% |
| Dec 31, 2021 | 183.73% |
| Sep 30, 2021 | -85.99% |
| Jun 30, 2021 | -68.55% |
| Mar 31, 2021 | -76.06% |
| Dec 31, 2020 | -57.14% |
| Sep 30, 2020 | 27.39% |
| Jun 30, 2020 | -67.45% |
| Mar 31, 2020 | -57.28% |